A recent study in Cancer Epidemiology, Biomarkers & Prevention indicates that the link between breast cancer and fertility drugs may not be as strong as previously suspected.
A recent study in Cancer Epidemiology, Biomarkers & Prevention indicates that the link between breast cancer and fertility drugs may not be as strong as previously suspected.
Researchers at the National Cancer Institute performed an extended follow-up on a cohort of 12,193 women who had been evaluated for infertility at 5 US sites between 1965 and 1988. Passive and active questionnaire techniques were used to achieve follow-up through 2010 with 81.1% of the eligible population (n = 9892). Hazard risks (HRs) and 95% confidence intervals (CIs) were determined through Cox regression.
Breast cancer was observed in 749 women over the course of the 30.0 median years of follow-up (285,334 person-years). Risk was not associated with ever use of clomiphene citrate among the 38.1% of patients who used the drug (HR = 1.05, 95% CI, 0.90-1.22 vs never use). Patients who underwent multiple cycles saw somewhat higher risks, with the risk of invasive forms of cancer being significantly elevated, according to medical records (HR = 1.69; 95% CI, 1.17-2.46). Even after adjusting for causes of infertility and multiple breast cancer predictors, the risk remained mostly unchanged. Gonadotropins were inconsistently associated with risk and used by 9.6% of women mainly in combination with clomiphene. The association reached significance, however, in women with invasive cancers who had taken the drugs and remained nulligravid (HR = 1.98; 95% CI, 1.04 – 3.60).
The study authors concluded that the connection between breast cancer risk and nulligravid women likely reflects on the underlying cause of infertility, whereas the risk associated with multiple clomiphene cycles remains unclear. They urged additional research on the long-term effects of fertility drugs on breast cancer, especially because the population studied was relatively young.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
PCOS and irregular cycles tied to cardiometabolic risks
May 15th 2024A comprehensive analysis reveals strong associations between polycystic ovary syndrome, irregular menstrual cycles, and increased risks of cardiometabolic conditions, underscoring the importance of proactive screening and intervention strategies.
Read More
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More
Advancing obstetric and gynecologic surgery through robotic innovation
April 30th 2024Explore how robotic surgery revolutionizes obstetric and gynecologic procedures, offering enhanced precision, reduced complications, and improved patient outcomes, while also examining challenges and future prospects in the field.
Read More